Working... Menu

NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00499122
Recruitment Status : Completed
First Posted : July 11, 2007
Results First Posted : March 29, 2013
Last Update Posted : January 2, 2018
Information provided by (Responsible Party):
University of Miami

Brief Summary:

RATIONALE: Oxidized glutathione (NOV-002) may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving NOV-002 together with chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

PURPOSE: This phase II trial is studying how well giving oxidized glutathione (NOV-002) together with doxorubicin and cyclophosphamide followed by docetaxel works in treating women with newly diagnosed stage II or stage III breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Cyclophosphamide Drug: Docetaxel Drug: Doxorubicin Drug: NOV 002 Phase 2

Detailed Description:

OUTLINE: This is a multicenter study.

Patients receive oxidized glutathione (NOV-002) IV twice on day -1 of course 1 and once on day 1 of courses 2-8. Patients receive NOV-002 subcutaneously once daily on days 2-21 of courses 1-8. Patients also receive chemotherapy comprising doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 of courses 1-4 followed by docetaxel IV on day 1 of courses 5-8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.

Patients undergo definitive surgery 3-6 weeks after completion of neoadjuvant therapy.

Blood samples are obtained at baseline and periodically during study to measure serum and plasma protein glutathionlylation. Additional blood samples are collected from some patients for immunological correlative studies.

After completion of study therapy, patients are followed at 30 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 41 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Neoadjuvant Treatment With NOV-002 in Combination With Doxorubicin and Cyclophosphamide Followed by Docetaxel in Patients With Stages IIB-IIIC Breast Cancer
Actual Study Start Date : June 4, 2007
Actual Primary Completion Date : April 2011
Actual Study Completion Date : April 2011

Arm Intervention/treatment
Experimental: NOV-002 and Chemotherapy
  • NOV-002:

    • Cycle 1, Day -1 only: 60 mg intravenously (IV) x 2, 3 hours (+/- 30 minutes) apart
    • Cycles 1 - 8, Day 1: 60 mg IV, 1 hour (+/- 30 minutes) prior to chemotherapy administration
    • Cycle 1 - 8, Days 2 - 21: 60 mg subcutaneous injections
  • Cyclophosphamide: 600 mg/m2 IV, Cycles 1 - 4, Day 1
  • Doxorubicin: 60 mg/m2 IV, Cycles 1 - 4, Day 1
  • Docetaxel: 100 mg/m2 IV, Cycles 5 - 8, Day 1
Drug: Cyclophosphamide
Other Name: Cytoxan

Drug: Docetaxel
Other Name: Cytoxan

Drug: Doxorubicin
Other Name: Adriamycin

Drug: NOV 002
Other Name: Oxidized glutathione

Primary Outcome Measures :
  1. Rate of Pathologic Complete Response in the Affected Breast After Protocol Therapy [ Time Frame: About 7 months ]
    The primary objective of this study is to define the rate of pathologic complete response rate (pCR) in the affected breast after the preoperative administration of NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with stage IIB-IIIC breast cancer. Pathologic complete response (pCR) is defined according to Hankoop et al [41] as either: the absence of any histological evidence of invasive breast cancer cells in the tissue specimen removed from the breast or the presence of invasive tumor equal to or less than 10mm after preoperative treatment, determined at definitive breast surgery.

Secondary Outcome Measures :
  1. Definition of the Safety Profiles of Protocol Therapy [ Time Frame: Up to 30 days Post-Last Dose of Protocol Therapy, About 7 months ]
    Definition of the safety profiles of protocol therapy in study participants as shown by the number of study participants experiencing adverse events or other toxicity.

  2. Correlation Between Myeloid Derived Suppressor Cell (MDSC) Levels and Pathologic Complete Response (pCR) and Non-Responders [ Time Frame: Baseline, Day 1 of Cycles 1 through 8, about 7 months ]
    The investigators hypothesized that patients with favorable responses, i.e. pCR, are more likely to have significantly lower levels of MDSCs than non-responders. MDSC levels will be measured at baseline and on day 1 of each treatment cycle, cycles 1 through 8.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 120 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Females age 18 years or older.
  • The ability to provide written informed consent prior to study specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time.
  • Histologically confirmed infiltrating (invasive) breast cancer by core needle biopsy, with no evidence of metastatic disease except to the ipsilateral axillary lymph nodes.
  • Clinical stage IIB - IIIC (T2-4, N0 or N1, M0 or - any T, N1-3, M0) breast cancer. The primary tumor must be greater than or equal to 2 cm (T2-4) or with pathologically proven axillary nodal involvement (N1-3).
  • Patients with inflammatory breast cancer (T4) are permitted into the study.
  • Clinically palpable tumor that meets the criteria of RECIST for palpable measurable disease. The primary tumor must be greater than or equal to 2 cm (T2-4) or with pathologically proven axillary nodal involvement (N1-3). Bilateral synchronic breast cancers are allowed but one of the primary tumors should be selected as the target tumor.
  • Primary tumor may be estrogen or progesterone receptor negative or positive, and human epidermal growth factor receptor 2 (HER-2/neu) negative as determined by either Fluorescent In Situ Hybridization (FISH) or 0-2+ staining by immunohistochemistry (IHC) (Hercept™).
  • Normal cardiac ejection fraction (EF ≥ 50%) as determined by screening multigated acquisition scan (MUGA) or echocardiogram.
  • No prior history of myocardial infarction, congestive heart failure, symptomatic coronary artery disease, or cardiac arrhythmias.
  • Patients must be ambulatory with Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
  • The patient or her caregiver must be able to self administer daily subcutaneous injections.
  • Life expectancy greater than 6 months.

Exclusion Criteria:

  • Prior therapy of any modality for the treatment of breast cancer
  • Any prior therapy with an anthracycline or a taxane for any other indication
  • HER-2 positive breast cancer defined as either gene amplification by Fluorescent In Situ Hybridization (FISH) or 3+ staining by IHC (Hercept™).
  • Women who have a positive pregnancy test, no pregnancy test available, who are pregnant or who are lactating.
  • Women of childbearing potential must agree to use a reliable and appropriate contraceptive method, which could include a double barrier method (condom plus diaphragm), an intrauterine device or oral contraceptives. Women with ER or PR positive breast cancer, should not, however, use oral contraceptives as a method of contraception. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential.
  • Women with breast cancer that do not have palpable breast tumors at screening.
  • History of another malignancy within the last 5 years except curatively treated basal cell carcinoma of the skin or cervical intraepithelial neoplasia.
  • Clinically significant (i.e. active) cardiac disease (NYHA Grade II or greater congestive heart failure, symptomatic coronary artery disease, unstable angina, and cardiac arrhythmia not well-controlled with medication), myocardial infarction within the last 6 months prior to study start, or screening ejection fraction of < 50%.
  • Any of the following abnormal laboratory values:

    • Absolute neutrophil count < 1.5 x 109/L
    • Platelet count < 100 x 109/L
    • Serum bilirubin > 1.5 x upper limit of normal (ULN)
    • Serum alanine transaminase (ALT), aspartate transaminase (AST) > 2.5 x ULN
    • Serum creatinine > 2.0 mg/dL or 177mmol/L or calculated creatinine clearance by the method of Cockcroft and Gault < 50mL/min).
  • Any severe or poorly controlled systemic disease (e.g., hypertension; clinically significant cardiovascular, pulmonary, or metabolic disease, disorders of wound-healing, ulcer or bone fracture).
  • Patients who have received any investigational treatment within 4 weeks of study start.
  • Known infection with HIV, Hepatitis B virus (HBV), or Hepatitis C virus (HCV).
  • Known hypersensitivity to any of the components of NOV-002 or to any of the study drugs.
  • Patients assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00499122

Layout table for location information
United States, Florida
University of Miami
Miami, Florida, United States, 33136
United States, South Carolina
Hollings Cancer Center at Medical University of South Carolina
Charleston, South Carolina, United States, 29425
Sponsors and Collaborators
University of Miami
Layout table for investigator information
Study Chair: Keisuke Shirai, MD Medical University of South Carolina
Principal Investigator: Alberto Montero, MD University of Miami

Publications of Results:
Layout table for additonal information
Responsible Party: University of Miami Identifier: NCT00499122     History of Changes
Other Study ID Numbers: 20071167
MUSC-101072 ( Other Identifier: Medical University of South Carolina )
MUSC-HR-17111 ( Other Identifier: Medical University of South Carolina )
First Posted: July 11, 2007    Key Record Dates
Results First Posted: March 29, 2013
Last Update Posted: January 2, 2018
Last Verified: December 2017

Keywords provided by University of Miami:
stage II breast cancer
stage IIIC breast cancer
inflammatory breast cancer

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Liposomal doxorubicin
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors